11th April 2018

UCI Statement on Rémy Di Gregorio

The Union Cycliste Internationale (UCI) announces that French rider Rémy Di Gregorio was notified of an Adverse Analytical Finding (AAF) of darbepoetin (dEPO)* in a sample collected on 8 March 2018 during Paris-Nice. This intelligence-led doping control was planned and carried out by the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the UCI, in charge of defining and implementing the anti-doping strategy in cycling, with the collaboration of the Agence Française de Lutte contre le Dopage (AFLD) and the Office central de lutte contre les atteintes à l’environnement et à la santé publique (OCLAESP).

The rider has the right to request and attend the analysis of the B sample. In accordance with UCI Anti-Doping Rules, the rider has been provisionally suspended until the adjudication of the affair. At this stage of the procedure, the UCI will not comment any further on this matter.

* dEPO is classified as “Peptide Hormones, Growth Factors, Related Substances and Mimetics” as per the World Anti-Doping Prohibited List.

• This media release was published by the international cycling union (UCI) on 11 April 2018. Click here for the original.

You may also like...

Pin It on Pinterest

Share This